Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

NCT03373760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

BIOLOGICAL: Durvalumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Tremelimumab

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]